Infants and children with dominant de novo mutations in GNAO1 exhibit movement disorders, epilepsy, or both. Children with loss-of-function (LOF) mutations exhibit Epileptiform Encephalopathy 17 (EIEE17). Gain-of-function (GOF) mutations or those with normal function are found in patients with Neurodevelopmental Disorder with Involuntary Movements (NEDIM).
INTRODUCTION
Neurodevelopmental Disorder with Involuntary Movements (NEDIM) is a newly defined neurological disorder associated with mutations in GNAO1. It is characterized by "hypotonia, delayed psychomotor development, and infantile or childhood onset of hyperkinetic involuntary movements" (OMIM 617493). NEDIM is monogenetic and related to GOF mutations in GNAO1, which was previously identified as a gene associated with early infantile epileptic encephalopathy 17 (EIEE17; OMIM 615473).
GNAO1 encodes Gα o , the most abundant membrane protein in the mammalian central nervous system 1 . Gα o is the α-subunit of the G o protein, a member of the G i/o family of heterotrimeric G proteins. G i/o proteins couples to many important G protein-coupled-receptors (GPCRs) involved in movement control like GABA B , dopamine D 2 , adenosine A 1 receptors and adrenergic α 2A receptors [2] [3] [4] [5] . Upon activation, Gα o and Gβγ separate from each other and modulate separate downstream signaling pathways including Gα o mediated inhibition of cyclic AMP (cAMP), Gβγ mediated inhibition of N-type calcium channels and Gβγ activation of G-protein activated inward rectifying potassium channels (GIRK channels) 6 . G o is expressed mainly in the central nervous system and it regulates neurotransmitter release by modulating intracellular calcium concentrations in pre-synaptic cells 7 . It has also been suggested that G o plays a role in neurodevelopmental processes like neurite outgrowth and axon guidance 8, 9 . Consequently, G o is an important modulator of neurological functions.
Previously, we defined a functional genotype-phenotype correlation for GNAO1 10 : GOF mutations are found in patients with movement disorders, while loss-of-fuction (LOF) mutations are associated with epilepsy 10 . An updated mechanistic review of this genotype-phenotype correlation was recently published 11 . The experimental study of mutant alleles, however, was done with human GNAO1 mutations expressed in HET293T cells, which lack a complex physiological content. Therefore, it would be important to see whether mouse models with GNAO1 mutations would share clinical characteristics of the human patients. Such a result would verify the previously -reported genotype-phenotype correlation and would provide a preclinical testing model for possible new therapeutics. Previously, we reported that heterozygous Gnao1 +/G184S mice carrying a human-engineered GOF mutation showed heightened sensitization to pentylenetetrazol (PTZ) kindling and had an elevated frequency of interictal epileptiform discharges on EEG 12 . Given the fact that GNAO1 GOF mutations are 4 associated with movement disorders, we wanted to ask whether Gnao1 +/G184S mice show both epilepsy and movement disorder phenotypes like 36% of patients with GNAO1 mutations.
G203R is a GOF GNAO1 mutation that is one of the more common GNAO1 mutations found clinically 11, [13] [14] [15] [16] [17] . Most patients with this mutation exhibit both seizures and movement disorders 11, [13] [14] [15] [16] [17] . We wanted to develop a mouse model with that mutation (Gnao1 +/G203R ) to see if it replicated the clinical phenotype of GNAO1 G203R associated neurological disorders.
In this report, we show that two Gα o GOF mutations Gnao1 +/G184S mice and Gnao1 +/G203R mice have sex-specific motor impairment and seizures and assess the possibility of using Gnao1 +/G184S and Gnao1 +/G203R mice as models to study GNAO1-associated neurological defects.
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MATERIALS & METHODS
Animals
Animal studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals established by the National Institutes of Health. All experimental protocols were approved by the Michigan State University Institutional Animal Care and Use Committee.
Mice were housed on a 12-h light/dark cycle and had free access to food and water. They were studied between 8-12 weeks old.
Generation of Gnao1 mutant mice
Gnao1 +/G184S mutant mice were generated as previously described 10, 12, 18, 19 and used as N10 or greater backcross on the C57BL/6J background.
Gnao1 G203R mutant mice were generated using CRISPR/Cas9 genome editing on the C57BL/6NCrl strain. gRNA targets within exon 6 of the Gnao1 locus (ENSMUSG00000031748) were used to generate the G203R mutation ( Figure 1A ). Synthetic single-stranded DNA oligonucleotides (ssODN) were used as repair templates carrying the desired mutation and short homology arms (Table 1) . CRISPR reagents were delivered as ribonucleoprotein (RNP) complexes. RNPs were assembled in vitro using wild-type S.p. Cas9 Nuclease 3NLS protein, and synthetic tracrRNA and crRNA (Integrated DNA Technologies, Inc.). TracrRNA and crRNA were denatured at 95°C for 5 min and cooled to room temperature in order to form RNA hybrids, which were incubated with Cas9 protein for 5 min at 37°C. RNPs and ssODN templates were electroporated into C57BL/6NCrl zygotes as described previously 20 , using a Genome Editor electroporator (GEB15, BEX CO, LTD). C57BL/6NCrl embryos were implanted into pseudo-pregnant foster dams. Founders were genotyped by PCR ( Table 1 ) followed by T7 Endonuclease I assay (M0302, New England BioLabs) and validated by Sanger sequencing.
Genotyping and Breeding
Heterozygous Gnao1 +/G203R mutant founder mice were crossed against C57BL/6J mice to generate Gnao1 +/G203R heterozygotes (N1 backcross). Further breeding was done to produce N2 backcross heterozygotes while male and female N1 heterozygotes were crossed to produce homozygous Gnao1 G203R/G203R mutants. Studies were done on N1 or N2 G203R heterozygotes with comparisons to littermate controls. 6 All mice had ears cliped prior before weaning. DNA was extracted from earclips by an alkaline lysis method 21 
Behavioral Studies
Researchers conducting behavioral experiments were blinded until the data analysis was completed. Before each experiment, mice were acclimated in the testing room for at least 10 min.
Open Field
The Open Field test was conducted in Fusion VersaMax 42 cm x 42 cm x 30 cm arenas (Omnitech Electronics, Inc., Columbus, OH). Mice and their littermate controls were placed in the arena for 30 minutes to observe spontaneous activities. Using the Fusion Software, distance traveled (cm) was evaluated for novel (first 10 minutes), sustained (10-30 minutes), and total (0-30 minutes) activity. Center Time was also measured. Center Time was defined as the time spent in the center portion (20.32cm x 20.32cm) of the Open Field cage.
RotaRod
Motor skills were assessed using an Economex accelerating RotaRod (Columbus Instruments, Columbus, OH). The entire training and testing protocol took two days. On day 1, mice were trained for three 2-minute sessions, with a 10-minute rest between each training period. During the first two sessions, the RotaRod was maintained at a constant speed of 5 rpm.
In the third training session, the rod was started at 5 rpm and accelerated at 0.1 rpm/sec for 2 minutes. On day 2, mice were trained with two more accelerating sessions for 2 minutes each with a 10-minute break in between. The final test session was 5 minutes long, starting at 5 rpm then accelerating to 35 rpm (0.1 rpm/sec). For all training and test trials, the time to fall off the 7 rod was recorded.
Grip Strength
Mouse grip strength data was collected following a protocol adapted from Deacon et al 22 using seven home-made weights (10, 18, 26, 34, 42, 49, 57 grams) . Briefly, the mouse was held by the middle/base of the tail and lowered to grasp a weight. A total of three seconds was allowed for the mouse to hold the weight with its forepaws and to lift the weight until it was clear of the bench. Three trials were done to permit the mice to lift the weights with a 10-second rest between each trial. If the mouse successfully held a weight for 3 seconds, the next heavier weight was given; otherwise the maximum time/weight achieved was recorded. A final total score was calculated based on the heaviest weight the mouse was able to lift up and the time that it held it 22 . The final score was normalized to the body weight of each mouse, which was measured before the trial.
DigiGait
Mouse gait data were collected using a DigiGait Imaging System (Mouse Specifics, Inc., Framingham, MA) 23 . The test is used for assessment of locomotion as well as the integrity of the cerebellum and muscle tone/equilibrium 24 . Briefly, after acclimation, mice were allowed to walk on a motorized transparent treadmill belt. A high-speed video camera was mounted below to capture the paw prints on the belt. Each paw image was treated as a paw area and its position recorded relative to the belt. Seven speeds (18, 20, 22, 25, 28, 32 and 36 cm/s) were tested per animal with a 5-minute rest between each speed. An average of 4-6 s of video was saved for each mouse, which is sufficient for the analysis of gait behaviors in mice 24 . For each speed, left & right paws were averaged for each animal while fore and hind paws were evaluated separately. Stride length was normalized to animal body length.
PTZ Kindling Susceptibility
A PTZ kindling protocol was performed as described before 12 to assess epileptogenesis.
Briefly, PTZ (40 mg/kg, i.p. in 5 mg/ml) was administered every other day starting at 8 weeks of age. Mice were monitored and scored for 30 minutes for behavioral signs of seizures as described 12, 25, 26 . Sensitization is defined as death or the onset of a tonic-clonic seizure on two consecutive treatment days. The number of injections for each mouse to reach a sensitization was reported in survival curves. 8 
Data Analysis
All data was analyzed using GraphPad Prism 7.0 (GraphPad; LaJolla, CA). Data are presented as mean ± SEM and a p value less than 0.05 was considered significant. All statistical tests are detailed in Figure Legends . Multiple comparison correction of the dataset from DigiGait was performed via a false discovery rate (FDR) correction at a threshold value of 0.01 in an R environment using the psych package.
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RESULTS
Gnao1 +/G203R mice showed normal viability and growth.
Genotypes of offspring of Gnao1 +/G203R x WT crosses (N1 -C57BL/6NCrl x C57BL/6J) were observed at the expected frequency (29 WT and 27 heterozygous). All three homozygous mice from Gnao1 +/G203R x Gnao1 +/G203R crosses died by P1. The small numbers of offspring observed from these crosses so far, however, were not significantly different from expected frequencies (4 wt, 14 het, and 3 homozygous). Heterozygous Gnao1 +/G203R mice did not show any growth abnormalities compared to Gnao1 +/+ mice ( Figure 1B & 1D) and they had relatively normal survival. There were two spontaneous deaths seen for Gnao1 +/G203R mice out of 33 ( Figure 1C ). This is reminiscent of the spontaneous deaths seen previously with the Gnao1 +/G184S GOF mutant mice 12 . Gnao1 +/G203R mice did not exhibit any obvious spontaneous seizures or abnormal movements.
Female Gnao1 +/G184S and male Gnao1 +/G203R mice show impaired motor coordination and reduced grip strength.
Since GOF alleles of GNAO1 in children result primarily in movement disorder, we tested motor coordination in both our engineered GOF mutant G184S and in the G203R GOF mutant seen in at least 7 children 10, 11 . This was initially assessed using a two-day training and testing procedure on the RotaRod (Figure 2A & B) . Gnao1 +/G184S and Gnao1 +/G203R mice were compared to their same-sex littermate controls. Female Gnao1 +/G184S mice exhibited a reduced retention time on the accelerating RotaRod (unpaired t-test, p<0.001, Figure 2A ) while male mice remained unaffected. In contrast, male Gnao1 +/G203R mice exhibited reduced time to stay on a rotating rod (unpaired t-test, p<0.05, Figure 2B ) while female Gnao1 +/G203R mice did not show any abnormalities. Results from all the RotaRod training and testing sessions are shown in Figure S1 .
Grip strength was assessed as described 22 . This test is widely done in combination with the RotaRod motor coordination test. This may be relevant to the hypotonia, seen in many GNAO1 patients 15, 16, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . Similar to the RotaRod results, female Gnao1 +/G184S mice also showed reduced forepaw grip strength compared to their littermate controls (unpaired student t-test, p<0.05, Figure 2C ) while males did not exhibit a significant difference ( Figure 2C ). In contrast, both male and female Gnao1 +/G203R mice displayed reduced forepaw grip strength (unpaired t-test, p<0.05, Figure 2D ).
Gnao1 +/G184S mice show reduced activity in the open field arena.
The open field test provides simultaneous measurements of locomotion, exploration and surrogates of anxiety. It is a useful tool to assess locomotive impairment in rodents 40 , however, environmental salience may reduce the impact of the motor impairment on behaviror 41 .
Therefore, we divided the 30-min open field measurements into two periods, with the first 10 min assessing activity in a novel environment and the 10-30 minute period as sustained activity ( Figure 3C & 3D) . The novelty measurement showed a significant difference between Gnao1 +/G184S mice and their littermate controls for both male and female mice (2-way ANOVA, p<0.01 for female, p<0.05 for male, Figure 3C ). Female but not male Gnao1 +/G184S mice showed Figure   S2 ).
Female Gnao1 +/G184S mice and male Gnao1 +/G203R mice exhibit markedly abnormal gaits.
In addition to the above behavioral tests, we also performed gait assessment on Gnao1 +/G184S and Gnao1 +/G203R mice of both sexes. Gait is frequently perturbed in rodent models of human movement disorders even when the actual movement behavior seen in the animals does not precisely phenocopy the clinical movement pattern 42, 43 . The multiple parameters assessed in DigiGait allow it to pick up subtle neuromotor defects and makes it more informative than the RotaRod test.
The gait analysis largely confirmed the sex differences between the two strains in RotaRod tests. Thirty seven parameters were measured for both front and hind limbs. Given the large number of measurements, we used false discovery rate (FDR) analysis with a Q of 1% as described in Methods to reduce the probability of Type I errors ( Figure S4 & S5, Table S1-S4).
Gnao1 +/G184S female mice showed 22 significant differences (Q<0.01) and males showed 8 ( Figure S4 , Table S3 & S4). For Gnao1 +/G203R mice, the opposite sex pattern was seen with 27 parameters in females and 8 parameters in males showing significant differences from WT ( Figure S5 , Table S1 & S2). Two of the most highly significant parameters and ones that had face validity in terms of clinical observations (stride length and paw angle variability) were chosen for further analysis.
Across the range of treadmill speeds, female Gnao1 +/G184S mice showed significantly reduced stride length (2-way ANOVA, p<0.01, Figure 4A ) and increased paw angle variability (2-way ANOVA, p<0.0001, Figure 4C ) compared to WT littermates. Male Gnao1 +/G184S mice only had a difference in paw angle variability ((2-way ANOVA, p<0.0001), not in stride length ( Figure 4E & 4G) . These results are consistent with the results of RotaRod and grip strength measurements in that female Gnao1 +/G184S mice showed a stronger phenotype for gait abnormalities than male. In contrast to the Gnao1 +/G184S mice, male Gnao1 +/G203R mice appeared to be more severely affected in gait compared to female Gnao1 +/G203R mice. Male Gnao1 +/G203R mice had highly significantly reduced stride length (2-way ANOVA, p<0.0001, Figure 4F ) and increased paw angle variability (2-way ANOVA, p<0.05, Figure 4H ). In contrast, female Gnao1 +/G203R mice did not show any significant differences in stride length or paw angle variability ( Figure 4B & 4D) .
In addition to these quantitative gait abnormalities a qualitative defect was seen. A significant number of Gnao1 +/G203R mice of both sexes failed to run when the belt speed exceeded 22 cm/s (Mann-Whitney test, female and male p<0.05, Figure 5B ). For reasons that are not clear such a difference was not seen for Gnao1 +/G184S mice ( Figure 5A ).
Male Gnao1 +/G203R mice are sensitized to PTZ kindling.
Epilepsy has been observed in 100% of patients with GNAO1 G203R mutations 11, 13-15, 17, 44 .
Also in the Gnao1 +/G184S GOF mutant mice, we previously reported spontaneous lethality as well as increased susceptibility to kindling by the chemical anticonvulsant PTZ for both males and females 12 . Kindling is a phenomenon where a sub-convulsive stimulus, when applied repetitively and intermittently, leads to the generation of full-blown convulsions 45 . To determine if the G203R GOF mutant mice mimicked the G184S mutants and phenocopied the human 12 epilepsy pattern of children with the G203R mutation, we assessed PTZ-induced kindling in Gnao1 +/G203R mutant mice. As expected for C57BL/6 mice, females were more prone to kindling than male mice with half kindled at 4 and 8-10 injections, respectively ( Figure 6A & 6B) . Despite the increased sensitivity of females in general, female Gnao1 +/G203R mice did not show significantly higher sensitivity to PTZ compared to their littermate controls ( Figure 6A ). On the contrary, male Gnao1 +/G203R mice were more sensitive to PTZ kindling than their controls ( Figure 6B , Mantel-Cox Test, p<0.05). Also, three spontaneous deaths were seen (two male and one female) among the 33 G203R mice observed for at least 100 days, similar to the early lethality seen in G184S mutant mice 12 . We cannot, however, attribute those deaths to seizures at this point. 13 
DISCUSSION
In this report, we describe the first mouse model carrying a human GNAO1 mutation associated with disease and we provide evidence to support the concept that GOF mutations are associated with movement disorder 10 . Heterozygous mice carrying the G203R mutation in Gnao1 exhibit both a mild increase in seizure propensity and evidence of abnormal movements.
This fits precisely with the variable seizure pattern of the children who carry this mutation as well as their severe choreoathetotic movements 11, 13-15, 17, 44, 46 . Also in this study, we examined a possible movement phenotype in the experimental mouse GOF mutant (Gnao1 +/G184S ) that we reported previously to have a mild seizure phenotype 12 . As predicted from our mechanistic model 10, 11 , it shows movement abnormalities as well.
In mouse models of movement disorders, the mouse phenotype is not as striking or as easily observed as the clinical abnormalities in the patients 47, 48 , however they are often informative about mechanism and therapeutics. For the patient-derived Gnao1 +/G203R mutant mouse, neither the seizure propensity nor the movement abnormality was obvious without a stress being applied. Male Gnao1 +/G203R mice showed decreased motor ability on RotaRod, decreased fore paw strength, and gait abnormalities at higher speeds of walking/running. No spontaneous seizures were observed but there was a substantial increase in sensitivity to PTZ-induced seizures in the kindling model. This very closely replicates the mild seizure phenotype of Gnao1 +/G184S mice 12 . We now show that the female Gnao1 +/G184S mice also exhibit gait and motor abnormalities.
Both the GNAO1 G203R and the G184S mutations show a definite but modest GOF phenotype in biochemical measurements of cAMP regulation 10 . In each case, the maximum percent inhibition of cAMP is not greatly increased but the potency of the α 2a adrenergic agonist, used in those studies to reduce cAMP levels, was increased about 2-fold. This effectively doubles signaling through these two mutant G proteins at low neurotransmitter concentrations (i.e. those generally produced during physiological signaling). This, however, does not prove that cAMP is the primary signal mechanism involved in pathogenesis of the disease. The heterotrimeric G protein, G o , of which the GNAO1 gene product, Gα o , is the defining subunit, can signal to many different effector mechanisms 8, 11, 49 . We recently reviewed the mutations associated with genetic movement disorders and identified both cAMP regulation and control of 14 neurotransmitter release as two GNAO1 mechanisms that seem highly likely to account for the pathophysiology of GNAO1 mutants 11 . Since many G o signaling effectors (including cAMP and neurotransmitter release) can be mediated by the Gβγ subunit released from the G o heterotrimer, other effectors could also be involved in the disease mechanisms. A recent hypothesis has also been raised that intracellular signaling by Gα o may be involved 50 . The observation that one of the most common movement disorder-associated alleles (R209H and other mutations in Arg 209 ) does not markedly alter cAMP signaling in in vitro models, does suggest that the mechanism is more complex than a simple GOF vs LOF distinction at cAMP regulation.
We observed a striking sex difference in the phenotypes of our two mouse models. Female Gnao1 +/G184S mice and male Gnao1 +/G203R mice showed much more prominent movement abnormalities than male G184S and female G203R mutants. However, the patterns of changes in the behavioral tests did not exactly overlap. Only G184S mutants showed significant changes in open field tests while only the G203R mutants showed the striking reduction in ability to walk/run at higher treadmill speeds. For both mutant alleles, the seizure phenotype was also worse in the sex with more prominent movement disorder. GNAO1 encephalopathy is slightly more prevalent (60:40) in female than male patients 11 . It is not uncommon to have sex differences in epilepsy or movement disease progression. One possible explanation is that estrogen prevents dopaminergic neuron depletion by decreasing the uptake of toxins into dopaminergic neurons in Parkinson's disease (PD) animal model induced by neurotoxin 51 . The G i/o coupled estrogen receptor, GPR30, also contributes to estrogen physiology and pathophysiology 52 . PD is more common in male than female human patients 53 , therefore, the pro-dopaminergic properties of estrogen may exacerbate conditions mediated by hyper-dopaminergic symptoms like chorea in Hungtington's disease (HD) 51 . Chorea/athetosis is the most prevalent movement pattern seen in GNAO1-associated movement disorders 11 so the female predominance correlates with that in HD. Clearly mechanisms of sex differences are complex including differences in synaptic patterns, neuronal densities and hormone secretion 51, 54, 55 , but it is beyond the scope of this report to explain how the molecular differences contribute to the distinct behavioral patterns.
Since GNAO1 encephalopathy is often associated with developmental delay and cognitive 15 impairment 11 , it would be interesting to see whether the movement phenotype we have seen in female Gnao1 +/G184S and male Gnao1 +/G203R mice is due to a neurodevelopmental malfunction or to ongoing active signaling alterations. G o coupled GPCRs play an important role in hippocampal memory formation 56, 57 . Additional behavioral tests will be valuble to assess the learning and memory ability of the Gnao1 mutant mice. There was no effect on stride length. (F & H) In contrast, male Gnao1 +/G203R mice showed markedly reduced stride length (2-way ANOVA p<0.0001 with Bonferroni multiple comparison post-test; ***p<0.001, **p<0.01, and *p<0.05) and modestly elevated paw angle variability (overall p<0.05). 
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